Could a fraction of the usual radiation be enough? new trial aims to reduce treatment burden for lymphoma patients.
NCT ID NCT05045664
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a much lower dose of radiation (4 Gy) combined with an antibody drug (obinutuzumab or rituximab) works as well as the standard high-dose radiation (24 Gy) plus rituximab for early-stage follicular lymphoma. About 100 adults with untreated stage I or II disease will take part. If successful, this approach could reduce radiation side effects while maintaining disease control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY STAGE FOLLICULAR LYMPHOMA WHO GRADE 1/2 OR 3A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Katharinen Hospital Stuttgart
RECRUITINGStuttgart, Germany
-
Krankenhaus Barmherzige Brüder
RECRUITINGRegensburg, 93049, Germany
-
LMU München
RECRUITINGMunich, 81377, Germany
-
Strahlentherapie KH Maria Hilf
RECRUITINGMönchengladbach, 41063, Germany
-
Technische Universität München
RECRUITINGMunich, 81675, Germany
-
University Hospital Heidelberg
RECRUITINGHeidelberg, 69120, Germany
-
University of Essen
RECRUITINGEssen, 45147, Germany
-
University of Göttingen
RECRUITINGGöttingen, 37075, Germany
-
University of Rostock
RECRUITINGRostock, 18057, Germany
-
University of Tübingen
RECRUITINGTübingen, 72076, Germany
-
University of Ulm
RECRUITINGUlm, 89081, Germany
-
Vivantes Klinikum Berlin
RECRUITINGBerlin, 10967, Germany